Does Rallies show 13F holders for IMCR?

Yes. Rallies tracks hedge fund and 13F ownership data for IMCR, including fund names, share counts, latest tracked quarter, and position changes when available.

Is IMCR research on Rallies investment advice?

No. Rallies provides research, data, and educational context for IMCR. It does not provide personalized investment advice.

IMCR (Immunocore Holdings plc American Depositary Shares) Stock Analysis - Hedge Fund Holdings

Immunocore Holdings plc American Depositary Shares (IMCR) is a publicly traded Healthcare sector company. As of May 21, 2026, IMCR trades at $29.55 with a market cap of $1.44B and a P/E ratio of -54.60. IMCR moved +2.14% today. Year to date, IMCR is -9.80%; over the trailing twelve months it is -8.80%. Its 52-week range spans $23.15 to $40.71. Analyst consensus is buy with an average price target of $62.33. Rallies surfaces IMCR's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns IMCR stock?

Hedge funds tracked by Rallies that own IMCR include Bridgewater Associates and Pentwater Capital. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Immunocore Holdings plc American Depositary Shares.

IMCR Key Metrics

Key financial metrics for IMCR
Metric	Value
Price	$29.55
Market Cap	$1.44B
P/E Ratio	-54.60
EPS	$-0.54
Dividend Yield	0.00%
52-Week High	$40.71
52-Week Low	$23.15
Volume	4
Avg Volume	0
Revenue (TTM)	$412.81M
Net Income	$-27.57M
Gross Margin	98.86%

Top Hedge Funds Holding IMCR

Bridgewater Associates holds 18.93K shares of IMCR, changed +90.21% as of Mar 31, 2026.
Pentwater Capital holds 15.00K shares of IMCR, changed +0.00% as of Jun 30, 2024.

Latest IMCR News

Immunocore Q1 KIMMTRAK Sales Climb 13.6% to $106.7M with $845M Cash — May 6, 2026
KIMMTRAK Five-Year Survival Doubles to 16% in Metastatic Uveal Melanoma — Apr 19, 2026
Rocket Companies to $22 Target, PennyMac to $115; Qualcomm Downgraded to Sell — Mar 16, 2026
Immunocore Posts 29% Sales Growth to $400M and $864M Cash Balance — Feb 25, 2026
Immunocore 2026 EPS Loss Estimates Narrow to $0.90, Shares Up 1.5% — Feb 20, 2026

Recent IMCR Insider Trades

Jallal Bahija sold 11.47K (~$371.18K) on Feb 18, 2026.
GOLL JOHN sold 698 (~$22.58K) on Feb 18, 2026.
St Leger Tina Amber sold 1.00K (~$32.35K) on Feb 18, 2026.

IMCR Analyst Consensus

10 analysts cover IMCR: 0 strong buy, 6 buy, 4 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $62.33.

Common questions about IMCR

Who owns IMCR stock?: Hedge funds tracked by Rallies that own IMCR include Bridgewater Associates and Pentwater Capital. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Immunocore Holdings plc American Depositary Shares.
Does Rallies show 13F holders for IMCR?: Yes. Rallies tracks hedge fund and 13F ownership data for IMCR, including fund names, share counts, latest tracked quarter, and position changes when available.
Is IMCR research on Rallies investment advice?: No. Rallies provides research, data, and educational context for IMCR. It does not provide personalized investment advice.